THE FIRST QUANT
ANALYTICS FOR BIOTECH

Strategy Signal is the leading provider of fundamental quantitative analyses of next-generation biotechnology companies. The Strategy Signal Quantitative Library and Models are used for interrogating and exploring relationships among variables to forecast future performance of biotech companies and stocks. Strategy Signal provides proprietary fundamental research to biopharma investors focused on efficiency, near-term alpha and timeliness.

FIND EXCLUSIVE INSIGHTS

Biotech
Pamela Bassett, DMD, MBA

Small Molecules Taking the Lead – Starting PTC Therapeutics (PTCT) Ahead of Key Data Catalysts 1H21

Recommendation Summary PTC Therapeutics (NASDAQ: PTCT, $57.23, BUY) is a rapidly emerging commercial-phase company focused primarily on neuromuscular and rare diseases, that we think has reached an inflection point, enabling and ensuring near- and longer-term growth. The company is proving its leadership position in small molecule RNA-focused drugs with its second product launched, Evrysdi (risdiplam), an RNA splice-modifying small-molecule to treat Spinal Muscular Atrophy (SMA). The company’s first RNA-focused small molecule, Translarna (ataluren), increases expression

Read More »